Neuropediatrics 2017; 48(03): 188-189
DOI: 10.1055/s-0037-1600112
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Lacosamide Lowers Valproate and Levetiracetam Levels

Maria Tountopoulou
1   Department of Pediatric Neurology, Center for Chronically Sick Children, Charité University Medicine Berlin, Berlin, Germany
,
Bernhard Weschke
1   Department of Pediatric Neurology, Center for Chronically Sick Children, Charité University Medicine Berlin, Berlin, Germany
,
Angela M. Kaindl
1   Department of Pediatric Neurology, Center for Chronically Sick Children, Charité University Medicine Berlin, Berlin, Germany
2   Institute of Cell Biology and Neurobiology, Charité University Medicine Berlin, Berlin, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

26. Dezember 2016

23. Januar 2017

Publikationsdatum:
21. März 2017 (online)

Abstract

Lacosamide (LCM) due to no known drug interaction and the absence of metabolic enzyme induction is a good candidate for an add-on medication, especially in combination with lamotrigine, levetiracetam (LEV), oxcarbazepine, topiramate, and valproic acid (VPA). Here we report for the first time, to our knowledge, that LCM can lower VPA and LEV serum levels. At present, there are no known explicable mechanisms of action of LCM, which lowers VPA and LEV. Here observed drug interaction of LCM is of clinical significance, which might be useful for other colleagues in the field.

Disclosure

There is no conflict of interest. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this communication adheres to those standards.